The Catalan pharmaceutical company Galenicum enters the Brazilian market
The expansion to Brazil is part of the company’s international development plan, which aims to start operations in Latin America, the Middle East and Asia. The company hopes to replicate its successful European business model overseas and has started with the opening of new offices in São Paulo. Galenicum, a developer of generic medicines, is based in Barcelona and produced a turnover of €77 million in 2011, a 542% increase in just two years.
Barcelona (ACN).- The Catalan pharmaceutical company Galenicum, developer of generic medicines, has opened new offices in São Paulo initiating its operations in the South American continent as part of its international expansion plan. Galenicum Brazil aims to replicate the innovative model that the company has applied in Europe from its headquarters in Barcelona. The company focuses on the development and licensing of generic products which produced a turnover of €77 million in 2011. João Keller led the opening of the offices in Brazil with a local team of professionals to address the particularities of the Brazilian market.
The expansion to Brazil is part of the company’s international development plan to start operations in Latin America, the Middle East and Asia. The success of its business model in Europe produced a turnover of €77 million in 2011, growing by 542% in just two years and establishing itself as a solid enterprise only 9 years after its foundation.